Abstract:Disease Overview The eosinophilias encompass a broad range of non‐hematologic (secondary or reactive) and hematologic (primary or clonal) disorders with the potential for end‐organ damage. Diagnosis Hypereosinophilia (HE) has generally been defined as a peripheral blood eosinophil count greater than 1.5 × 109/L, and may be associated with tissue damage. After the exclusion of secondary causes of eosinophilia, diagnostic evaluation of primary eosinophilias relies on a combination of various tests. They include morphologic review of the blood and marrow, standard cytogenetics, fluorescence in situ hybridization, molecular testing and flow immunophenotyping to detect histopathologic or clonal evidence for an acute or chronic hematolymphoid neoplasm. Risk Stratification Disease prognosis relies on identifying the subtype of eosinophilia. After evaluation of secondary causes of eosinophilia, the 2022 World Health Organization and International Consensus Classification endorse a semi‐molecular classification scheme of disease subtypes. This includes the major category "myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions" (MLN‐eo‐TK), and the MPN subtype, "chronic eosinophilic leukemia" (CEL). Lymphocyte‐variant HE is an aberrant T‐cell clone‐driven reactive eosinophila, and idiopathic hypereosinophilic syndrome (HES) is a diagnosis of exclusion. Risk‐Adapted Therapy The goal of therapy is to mitigate eosinophil‐mediated organ damage. For patients with milder forms of eosinophilia (e.g., <1.5 × 109/L) without symptoms or signs of organ involvement, a watch and wait approach with close follow‐up may be undertaken. Identification of rearranged PDGFRA or PDGFRB is critical because of the exquisite responsiveness of these diseases to imatinib. Pemigatinib was recently approved for patients with relapsed or refractory FGFR1‐rearranged neoplasms. Corticosteroids are first‐line therapy for patients with lymphocyte‐variant HE and HES. Hydroxyurea and interferon‐α have demonstrated efficacy as initial treatment and in steroid‐refractory cases of HES. Mepolizumab, an interleukin‐5 (IL‐5) antagonist monoclonal antibody, is approved by the U.S Food and Drug Administration for patients with idiopathic HES. Cytotoxic chemotherapy agents, and hematopoietic stem cell transplantation have been used for aggressive forms of HES and CEL, with outcomes reported for limited numbers of patients. Targeted therapies such as the IL‐5 receptor antibody benralizumab, IL‐5 monoclonal antibody depemokimab, and various tyrosine kinase inhibitors for MLN‐eo‐TK, are under active investigation.

Biologics in Hypereosinophilic Syndrome and Eosinophilic Granulomatosis with Polyangiitis

Biologics and Hypereosinophilic Syndromes: Knowledge Gaps and Controversies

HES and EGPA: Two Sides of the Same Coin

An International, Retrospective Study of Off-Label Biologic Use in the Treatment of Hypereosinophilic Syndromes

Eosinophilic granulomatosis with polyangiitis – Advances in pathogenesis, diagnosis, and treatment

Therapeutic advances in eosinophilic granulomatosis with polyangiitis

Advancements in Biologic Therapies for Eosinophilic Gastrointestinal Diseases: A Comprehensive Review

The Role of T Helper Type 2 (Th2) Cytokines in the Pathogenesis of Eosinophilic Granulomatosis with Polyangiitis (eGPA): an Illustrative Case and Discussion

Expert consensus on the use of systemic glucocorticoids for managing eosinophil-related diseases

World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management

Pathogenesis, classification, and therapy of eosinophilia and eosinophil disorders

[Eosinophilic granulomatosis with polyangiitis: a review article]

Mesenchymal stem cell therapy in eosinophilic granulomatosis with polyangiitis-related lower limb gangrene: a case report

Clinical and Therapeutic Intervention of Hypereosinophilia in the Era of Molecular Diagnosis

Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis

Targeted Therapies for Eosinophilic Gastrointestinal Disorders

Eosinophilic granulomatosis with polyangiitis: A review

Hypereosinophilia In A Complex Post Transplant Pediatric Patient

Long-Term Effectiveness of Benralizumab in Eosinophilic Granulomatosis With Polyangiitis

A Review of Anti-IL-5 Therapies for Eosinophilic Granulomatosis with Polyangiitis

Ten clinical conundrums in the management of eosinophilic granulomatosis with polyangiitis